UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

HSF1 Pathway Inhibitor Clinical Candidate (CCT361814/NXP800) Developed from a Phenotypic Screen as a Potential Treatment for Refractory Ovarian Cancer and Other Malignancies

Pasqua, AE; Sharp, SY; Chessum, NEA; Hayes, A; Pellegrino, L; Tucker, MJ; Miah, A; ... Cheeseman, MD; + view all (2023) HSF1 Pathway Inhibitor Clinical Candidate (CCT361814/NXP800) Developed from a Phenotypic Screen as a Potential Treatment for Refractory Ovarian Cancer and Other Malignancies. Journal of Medicinal Chemistry , 66 (8) pp. 5907-5936. 10.1021/acs.jmedchem.3c00156. Green open access

[thumbnail of HSF1 Pathway Inhibitor Clinical Candidate (CCT361814NXP800) Developed from a Phenotypic Screen as a Potential Treatment for .pdf]
Preview
PDF
HSF1 Pathway Inhibitor Clinical Candidate (CCT361814NXP800) Developed from a Phenotypic Screen as a Potential Treatment for .pdf - Published Version

Download (3MB) | Preview

Abstract

CCT251236 1, a potent chemical probe, was previously developed from a cell-based phenotypic high-throughput screen (HTS) to discover inhibitors of transcription mediated by HSF1, a transcription factor that supports malignancy. Owing to its activity against models of refractory human ovarian cancer, 1 was progressed into lead optimization. The reduction of P-glycoprotein efflux became a focus of early compound optimization; central ring halogen substitution was demonstrated by matched molecular pair analysis to be an effective strategy to mitigate this liability. Further multiparameter optimization led to the design of the clinical candidate, CCT361814/NXP800 22, a potent and orally bioavailable fluorobisamide, which caused tumor regression in a human ovarian adenocarcinoma xenograft model with on-pathway biomarker modulation and a clean in vitro safety profile. Following its favorable dose prediction to human, 22 has now progressed to phase 1 clinical trial as a potential future treatment for refractory ovarian cancer and other malignancies.

Type: Article
Title: HSF1 Pathway Inhibitor Clinical Candidate (CCT361814/NXP800) Developed from a Phenotypic Screen as a Potential Treatment for Refractory Ovarian Cancer and Other Malignancies
Location: United States
Open access status: An open access version is available from UCL Discovery
DOI: 10.1021/acs.jmedchem.3c00156
Publisher version: http://dx.doi.org/10.1021/acs.jmedchem.3c00156
Language: English
Additional information: © 2023 The Authors. Published by American Chemical Society. This publication is licensed under CC-BY 4.0.
Keywords: Humans, Female, Transcription Factors, Ovarian Neoplasms, Cell Line, Tumor, Antineoplastic Agents
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Department of Neuromuscular Diseases
URI: https://discovery.ucl.ac.uk/id/eprint/10184910
Downloads since deposit
14Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item